Literature DB >> 602346

Studies on lymphocytotoxicity in acute and chronic liver disease.

H Warnatz, W Gutmann, W Rösch, G Hommel.   

Abstract

The cytotoxicity of lymphocytes from patients with chronic active hepatitis, chronic persistent hepatitis, acute hepatitis B and rheumatoid arthritis as well as from normal controls was studied in a microcytotoxicity assay according to COHEN et al. using 125I-iododeoxyuridine labeled embryonal liver cells and Chang cells as target cells. Unfractionated lymphocytes of the peripheral blood from patients with chronic active hepatitis and rheumatoid arthritis showed a high frequency of cytotoxic activity. The lymphocytotoxicity in chronic active hepatitis was significantly increased in comparison to normal controls at the EC/TC of 10:1 and 100:1. Specificity of the cytotoxic reaction to target cells could not be demonstrated. Addition of autologous serum to the cytotoxic assay blocked the lymphocytotoxicity in patients with chronic active hepatitis. A weak potentiating effect on lymphocytotoxicity was observed in patients with hepatitis B after addition of autologous serum. It is discussed that this reaction is due to the presence of HB-antigen in the serum since addition of HB-antigen from other sources increased also the lymphocytotoxicity in hepatitis B patients. This effect was observed neither in HB-antigen positive nor in HB-antigen negative patients with chronic active hepatitis or chronic persistent hepatisis.

Entities:  

Mesh:

Year:  1977        PMID: 602346

Source DB:  PubMed          Journal:  Z Immunitatsforsch Immunobiol        ISSN: 0340-904X


  2 in total

1.  Antibody-dependent cell-mediated cytotoxicity (ADCC) and cell-mediated cytotoxicity (CMC) to HBsAg-coated target cells in patients with hepatitis B and chronic hepatitis (CAH).

Authors:  H Warnatz; W Rösch; W Gerlich; W Gutmann
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

2.  Studies on immunoregulatory mechanisms in acute and chronic hepatitis B.

Authors:  G Lemm; K Salzer; H Warnatz
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.